{"version":"1.0","provider_name":"Department of Medicine","provider_url":"https:\/\/www.med.unc.edu\/medicine","author_name":"Kim Morris","author_url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/","title":"Clinicians May Underreport Adverse Events in Phase 1 Trials | Department of Medicine","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"1g4yxpVogw\"><a href=\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/\">Clinicians May Underreport Adverse Events in Phase 1 Trials<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.med.unc.edu\/medicine\/news\/clinicians-may-underreport-adverse-events-phase-1-trials\/embed\/#?secret=1g4yxpVogw\" width=\"600\" height=\"338\" title=\"&#8220;Clinicians May Underreport Adverse Events in Phase 1 Trials&#8221; &#8212; Department of Medicine\" data-secret=\"1g4yxpVogw\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/basch-research-image2.jpeg","thumbnail_width":400,"thumbnail_height":500,"description":"Patient-clinician agreement for symptomatic adverse events in phase 1 trials appeared moderate to poor, suggesting clinicians are underreporting toxicity, according to a study published in the Journal of the National Cancer Institute. Ethan\u00a0Basch, MD, MSc, the Richard M. Goldberg Distinguished Professor of Medical Oncology and director of the UNC Cancer Outcomes and Research Program at &hellip; Read more"}